# STAAR Surgical Company > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/STAAR Surgical Company). ## Overview STAAR Surgical designs, manufactures, and sells implantable lenses for the eye and the accessory delivery systems used to place them. Its core business centers on Collamer® implantable collamer lenses (ICLs), which are used in refractive eye surgery and sold across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. ## Products & services • Implantable Collamer® lenses (ICLs) • Phakic refractive lens implants • Foldable lens delivery systems • Surgeon training and procedure support • Refractive vision correction solutions - **Implantable Collamer® lenses (ICLs)** (90%) — Phakic implantable lenses used in refractive surgery to correct vision without removing the natural lens. - **Accessory delivery systems** (10%) — Devices and tools used by surgeons to deliver ICLs into the eye during procedures. - Implantable Collamer® lenses (ICLs) - Phakic refractive lens implants - Foldable lens delivery systems - Surgeon training and procedure support - Refractive vision correction solutions ## Customers Customers are ophthalmic surgeons, refractive surgery centers, and eye-care providers that perform elective vision-correction procedures. The end patients are typically adults seeking alternatives to eyeglasses or contact lenses, especially where ICLs are preferred for high refractive error or when corneal tissue removal is less suitable. - **Refractive surgeons and surgical centers** (primary) — Buy ICLs and delivery systems for elective refractive procedures and value predictable surgical workflow. - **International distributors** (primary) — Purchase and distribute ICL products in markets served through channel partners. - **Ophthalmology clinics** (secondary) — Use the lenses in vision-correction procedures and rely on surgeon education and support. - **Patients seeking refractive correction** (secondary) — End users who choose ICL procedures for visual freedom and reversible lens implantation. - Refractive surgeons performing elective vision-correction procedures - Ophthalmology clinics and surgical centers - Distributor partners in international markets - Patients seeking alternatives to glasses or contact lenses - Providers needing training and procedural support ## Geography STAAR sells worldwide, with business concentrated in Asia-Pacific, EMEA, and the Americas. The company specifically cites sales growth in Korea, Japan, China, India, Canada, the U.S., and Latin America distributor markets, showing a geographically diversified refractive-surgery footprint. - **Asia Pacific** (0%) — Regional sales disclosed, but no exact share percentage provided in excerpts. - **Europe, Middle East and Africa** (0%) — Regional sales disclosed, but no exact share percentage provided in excerpts. - **Americas** (0%) — Regional sales disclosed, but no exact share percentage provided in excerpts. - APAC is a major sales region and includes China, Japan, Korea, and India - EMEA includes both distributor and direct markets - The Americas include the U.S., Canada, and Latin America distributors - China is an important market and can drive quarter-to-quarter swings - Foreign currency movements affect reported sales and comparability ## Strategy STAAR’s strategy is to expand the availability of its full ICL product line in existing markets while entering additional countries where refractive surgery demand can support adoption. It also emphasizes awareness-building, surgeon training, and clinical education to increase procedure adoption and strengthen its position in newer markets. - **Broaden market access for the ICL portfolio** (medium-term) — A wider product footprint increases procedure adoption and deepens penetration in served markets. - **Build surgeon awareness and training** (short-term) — ICL adoption depends on surgeon familiarity, procedural confidence, and patient education. - **Support sustainable commercialization** (medium-term) — The business relies on recurring procedure volume and distributor/surgeon engagement across regions. - Expand the full ICL line across existing markets - Enter attractive new geographies for refractive surgery - Increase awareness of the ICL procedure and benefits - Support surgeons with training and education - Use commercialization to drive sustainable growth ## Risks STAAR is exposed to demand concentration in refractive surgery markets, especially China and other APAC countries, where regional swings can materially affect sales. It also faces execution risk around product adoption, distributor performance, regulatory approvals, and the costs and uncertainties tied to the proposed merger process described in the filing. - **China demand volatility** [high] — A large portion of sales is tied to APAC, and China sales have shown sharp swings in reported periods. - **Market adoption and surgeon education risk** [medium] — ICL procedures require surgeon familiarity and patient acceptance to expand volume. - **Distributor/channel execution risk** [medium] — International sales rely partly on distributor markets, which can affect inventory, sell-through, and pricing. - **Merger-related transaction risk** [high] — The filing describes stockholder approval, litigation, and regulatory conditions that may not be satisfied. - **Foreign exchange exposure** [medium] — Global sales create translation and transaction exposure across multiple currencies. - China and APAC demand can swing sharply quarter to quarter - Refractive surgery adoption depends on surgeon training and awareness - Distributor performance affects international sales execution - Regulatory approvals can delay or block strategic transactions - Foreign exchange movements can affect reported revenue ## Accounting Revenue is primarily recognized from product sales of ICLs and related delivery systems, so shipment timing and sales return allowances can affect quarterly comparability. The company also has judgment-heavy items such as restructuring and impairment charges, lease accounting for properties, and estimates around working capital and liquidity that can materially change reported results. - **Revenue recognition and sales return allowances** — Quarterly revenue comparability - **Restructuring and impairment charges** — Operating expense and asset carrying values - **Lease accounting and right-of-use assets** — Balance sheet and expense recognition - **Foreign currency effects** — Reported revenue and other income - Product revenue timing affects quarterly comparability - Sales return allowances can reduce recognized net sales - Restructuring and impairment charges can be material - Lease and right-of-use asset accounting affects expenses - Estimates and assumptions drive asset and liability values --- *Last updated: 2026-04-29T04:56:26.843483+00:00*